Pharming Group (PHGUF) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Pharming Group (OTCMKTS:PHGUF) from a hold rating to a sell rating in a research report released on Wednesday morning.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other analysts have also issued reports on the stock. ValuEngine lowered shares of Pharming Group from a hold rating to a sell rating in a research note on Friday, December 1st. HC Wainwright reiterated a buy rating on shares of Pharming Group in a research note on Thursday, October 26th.

Shares of Pharming Group (PHGUF) opened at $1.50 on Wednesday. Pharming Group has a 12 month low of $0.30 and a 12 month high of $1.58. The company has a current ratio of 1.77, a quick ratio of 1.27 and a debt-to-equity ratio of 11.72.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2018/01/14/pharming-group-phguf-stock-rating-lowered-by-zacks-investment-research.html.

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit